



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

- Name of Inspector from whom received : Lianhmingthangi, (Assistant Drugs Inspector (F and D))
Siaha District, Mizoram- 796901
- Serial No. and date of Inspector's memorandum : SD/26/12N-DRUGS , 25-MAR-2026
- Number of Sample : NIL
- Date of receipt : 20-APR-2026
- Names of drugs purporting to be contained in the sample : Pantoprazole Gastro-resistant & Domperidone
Prolonged-release Capsules I.P. (Pantas-DSR)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2026-GUW/LS/2026-27/0186	27/155	YC489B	Aug-2025 Jul-2027	NA	Saphnix Life Sciences, Village-Barotiwala, Paonta Sahib, Distt. Sirmour, Himachal Pradesh-173025

6. Condition of seals on : Seals were intact & identical to the
[the packet or on portion of sample or container] specimen impression of the seal received
from Drugs Inspector

7. Result of test or analysis with protocols or test or analysis applied : Please see below

Date of Testing : From 05-May-2026 To 01-Jun-2026

COMPOSITION : Each hard gelatin capsule contains:
Pantoprazole Sodium I.P. Eq. to Pantoprazole 40 mg.
(As Gastro-Resistant Pellets)
Domperidone I.P. 30 mg.
(As Prolonged-Release Pellets)

Protocol Applied : I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	Orange and blue colored pellets filled in transparent pink colored and colorless hard gelatin capsules, in blister pack.	NA
2	Identification	Gives positive test for Pantoprazole Sodium & Domperidone.	NA
3	Filled Content	0.26957 g	NA
4	Dissolution	Complies for Pantoprazole.	
5	Dissolution For Pantoprazole (Acid Stage)	Complies.	NMT 10 % of claim

6	Dissolution For Pantoprazole (Buffer Stage)	Complies.	NLT 70 % of claim
---	---	-----------	-------------------

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
1	Pantoprazole Sodium eq. to Pantoprazole	38.91 mg/Capsule	40 mg/Capsule	97.275	90 % to 110 %	I.P. 2022
2	Domperidone	30.06 mg/Capsule	30 mg/Capsule	100.2	90 % to 110 %	I.P. 2022

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per I.P. 2022 in respect of test performed.

Date: 16-JUN-2026

GOVERNMENT ANALYST

Rinku Kalita
Government Analyst
R.D.T.L., Guwahati-22

END OF REPORT

